ADRB2 Polymorphisms and Asthma Susceptibility: Transmission Disequilibrium Test and Meta-Analysis
ADRB2 Polymorphisms and Asthma Susceptibility: Transmission Disequilibrium Test and Meta-Analysis
复制标题
DOI：
10.1159/000078648
复制
发表时间：
2004-06
影响因子：
2.8
通讯作者：
O. Migita;E. Noguchi;Z. Jian;M. Shibasaki;T. Migita;K. Ichikawa;A. Matsui;T. Arinami
中科院分区：
文献类型：
--
作者：
O. Migita;E. Noguchi;Z. Jian;M. Shibasaki;T. Migita;K. Ichikawa;A. Matsui;T. Arinami
背景资料：β 2-肾上腺素能受体（ADRB 2）是肺中最常见的肾上腺素能受体，已报道了ADRB 2多态性与哮喘中间表型之间的关联。在ADRB 2信使RNA的5 ′前导顺反子中发现了4个错义多态性（Arg16Gly、Gln27Glu、Val34Met和Thr164Ile）和1个多态性。体外研究表明，这些错义多态性可以影响ADRB 2功能。研究方法：为了研究ADRB 2多态性与哮喘易感性之间的可能联系，我们对137个日本特应性哮喘患儿家庭进行了传递不平衡检验（TDT）。结果：经TDT检测，未发现ADRB 2基因多态性与哮喘的发生有关联（p> 0.1）。我们还对所有可用研究的数据进行了荟萃分析。随机效应模型显示Arg16Gln（比值比= 1.05，p = 0.53）或Gln27Glu（比值比= 1.12，p = 0.22）多态性无显著比值比。结论：我们的数据表明ADRB 2对哮喘易感性没有实质性贡献，但这些多态性可能影响哮喘患者的疾病活动和药物反应。
Background: The β2-adrenergic receptor (ADRB2) is the most common adrenergic receptor in the lung, and associations between ADRB2 polymorphisms and intermediate phenotypes of asthma have been reported. Four missense polymorphisms (Arg16Gly, Gln27Glu, Val34Met, and Thr164Ile) and one polymorphism in the 5′ leader cistron of the ADRB2 messenger RNA has been identified. In vitro studies have shown that these missense polymorphisms can affect ADRB2 function. Methods: To examine possible associations of ADRB2 polymorphisms with asthma susceptibility, we performed transmission disequilibrium tests (TDT) of 137 Japanese families identified through children with atopic asthma. Results: We did not find associations between any alleles of the ADRB2 polymorphisms and asthma by TDT (p > 0.1). We also performed a meta-analysis of data from all available studies. The random-effects model showed no significant odds ratio for the Arg16Gln (odds ratio = 1.05, p = 0.53) or Gln27Glu (odds ratio = 1.12, p = 0.22) polymorphism. Conclusion: Our data indicate that ADRB2 does not contribute substantially to susceptibility to asthma, but it is possible that these polymorphisms influence disease activity and drug responses in individuals with asthma.